US Pharma MarketingThe post Agenus’ metastatic colorectal cancer combo achieves 33% three-year OS rate appeared first on Clinical Trials Arena.
Agenus’ metastatic colorectal cancer combo achieves 33% three-year OS rate
Three-year data from the Phase Ib trial of BOT+BAL in patients with colorectal cancer were unveiled at ESMO GI 2026. Three-year data from the Phase Ib trial of BOT+BAL was unveiled at ESMO GI 2026. With extended follow-up, median OS was 21.2 months and the three-year OS rate was 33%. Credit: crystal light / Shutterstock.com Agenus’s metastatic colorectal cancer (mCRC) combination therapy has continued to show benefit after three years of treatment, with a median overall survival (OS) of 21.2 months. In the Phase Ib trial (NCT03860272), patients received a combination of botensilimab (BOT), an Fc-enhanced multifunctional anti–CTLA-4 antibody, plus…
Three-year data from the Phase Ib trial of BOT+BAL in patients with colorectal cancer were unveiled at ESMO GI 2026.
Source: Clinical Trials Arena